Funding for this research was provided by:
Received: 26 October 2021
Accepted: 2 July 2022
First Online: 25 July 2022
: The local institutional review board of the Amsterdam UMC, location VUmc (Amsterdam, The Netherlands) approved the study. All subjects provided written informed consent prior to the study.
: Not applicable.
: Dr Scheltens has received consultancy fees (paid to the institution) from AC Immune, Alkermes, Alnylam, Alzheon, Anavex, Biogen, Brainstorm Cell, Cortexyme, Denali, EIP, ImmunoBrain Checkpoint, GemVax, Genentech, Green Valley, Novartis, Novo Nordisk, PeopleBio, Renew LLC, and Roche. He is PI of studies with AC Immune, CogRx, FUJI-film/Toyama, IONIS, UCB, and Vivoryon. He is a part-time employee of Life Sciences Partners Amsterdam. He serves on the board of Brain Research Center and New Amsterdam Pharma. The other authors declare that they have no competing interests.